Reporter
-
December 13, 2018
VUMC Addiction Consultation Service sees rising demand
An Addiction Consultation Service, specialized training for physicians and changes in the language used in addiction cases are the first of many in a series of new clinical approaches being offered around addiction care as Vanderbilt University Medical Center — and the rest of the country — see an increased demand for such services. -
December 13, 2018
Lean vs. obese adipose tissue cells
A greater understanding of the mechanisms and cell types involved in returning adipose (fatty) tissue to the lean state may lead to more effective treatments for obesity. -
December 13, 2018
Policies for Action Research Hub at Vanderbilt created
Experts from Vanderbilt University School of Medicine’s Department of Health Policy and Vanderbilt University’s Peabody College of Education and Human Development are joining efforts to establish a Policies for Action (P4A) Research Hub at Vanderbilt to better understand and develop recommendations to address the needs of some of Tennessee’s most vulnerable children, including those in immigrant families and with prenatal exposure to opioids. -
December 13, 2018
Study links soy formula feeding and menstrual pain
Researchers at the National Institute of Environmental Health Sciences (NIEHS), with the help of an epidemiologist at Monroe Carell Jr. Children’s Hospital at Vanderbilt, recently published findings showing an association between infant soy formula feeding and menstrual pain in adulthood. -
December 13, 2018
Philip’s liver cancer research receives V Foundation support
Mary Philip, MD, PhD, has been named a 2019 V Scholar and will receive $200,000 from the V Foundation for Cancer Research. -
December 13, 2018
Breast cancer-killing RIG
A compound that activates a virus-sensing receptor has potent therapeutic effects in a mouse model of breast cancer. -
December 13, 2018
Therapy aims to reduce prostate cancer treatment side effects
Vanderbilt urologic surgeons are offering an alternative therapy for prostate cancer patients considered to be low-to-intermediate risk, a middle ground between active surveillance and aggressive therapy.